Berkeley, CA, February 18, 2021 – GeneTether Inc., a Bay Area biotech company focused on developing technologies to increase the correction efficiency of targeted genome editing technologies, today announced that Har Grover has joined the Company as the Co-Founding CEO and as a shareholder.
William Garner, MD, Co-Founder and Director of GeneTether, stated: “We are pleased to have Har Grover join the company. He has a strong track record in building life sciences companies at every stage of growth, and we are confident in his ability to build on the strong foundation that has been established since Geoff Sargent and I formed the company from Geoff’s scientific breakthroughs.”
“The Company has hit its initial milestones in protecting its intellectual property” said Geoffrey Sargent, PhD, Co-Founder and CSO of GeneTether, ”We look forward to Har now leading our efforts on the company building activities.”
In addition to Mr. Grover joining GeneTether, the Company is reorganizing its board of directors, with the addition of Daren Graham as Chair, and the addition of Andre Fraga as an Independent Director.
GeneTether has developed a proprietary method to conjugate, or “tether,” donor DNA templates to targeted genome editing technologies, including CRISPR-Cas, TALENs, and ZFNs. We refer to this as our DNA Template-Nuclease Tethering, or TNT™, Platform. In ex vivo experimentation combining our TNT™ Platform technology with CRISPR-Cas9, the TNT™ Platform has been shown to increase editing efficiency to >50%.
For more information, visit www.genetether.com.
For inquiries, please contact us at:
Har Grover, CEO